STOCK TITAN
  1. Home
  2. Sec-filings
  3. KA
  4. [EFFECT] Kineta, Inc. Common Stock SEC Filing

[EFFECT] Kineta, Inc. Common Stock SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
Rhea-AI Filing Summary
-
-
-
-
-
Positive
  • None.
Negative
  • None.
-
-
-
-
-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 1, 2025
Accession Number: 0001193125-25-152902
Submission Type: POS AM
CIK: 0001445283
Company Name: KINETA, INC./DE
File Number: 333-272326

Source: View Original Filing on SEC EDGAR

Stock KA logo
Kineta, Inc.

NASDAQ:KA

KA Rankings

#9978 Ranked by Market Cap
N/A Ranked by Dividends

KA Latest News

Oct 8, 2024
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
Oct 4, 2024
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Oct 2, 2024
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
Sep 19, 2024
Kineta, Inc Transitioning from Nasdaq to OTC Markets
Aug 19, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

KA Latest SEC Filings

Jul 2, 2025
[15-12G] Kineta, Inc. Common Stock SEC Filing
Jul 2, 2025
[Form 4] Kineta, Inc. Common Stock Insider Trading Activity
Jul 2, 2025
[Form 4] Kineta, Inc. Common Stock Insider Trading Activity
Jul 2, 2025
[Form 4] Kineta, Inc. Common Stock Insider Trading Activity
Jul 2, 2025
[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

KA Stock Data

7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
MERCER ISLAND